Streptococcus pneumoniae: Description of the Pathogen, Disease Epidemiology, Treatment, and Prevention
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Streptococcus pneumoniae causes significant morbidity and mortality. Children younger than 2 years and individuals older than 65 years experience the highest rates of pneumococcal disease. Efforts to treat pneumococcal disease have been complicated by increasing resistance to antimicrobials. Prevention efforts have included the pneumococcal polysaccharide vaccines and the pneumococcal conjugate vaccines, with use of these vaccines targeted to those at highest risk for disease. Information and background on S. pneumoniae and pneumococcal disease are provided. Vaccines targeted at this pathogen are reviewed, and the clinical trials that evaluated their safety, efficacy, and effectiveness are summarized. Also provided are recommendations for use of these vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Streptococcus pneumoniae colonisation: the key to pneumococcal disease
Bogaert, D., de Groot, R., & Hermans, P. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)00938-7 · Cited by 1,929 · cited 1×
“Asymptomatic colonization is especially high in children and plays a key role in pneumococcal disease and pneumococcal spread.(10) Nasopharyngeal carriage rates range from 5–30% of healthy adults 12 and from 20–50% of healthy children.”
BackgroundAcute Bacterial Meningitis in Adults -- A Review of 493 Episodes
Durand, M. L., Calderwood, S. B., Weber, D. J., Miller, S. I., Southwick, F. S., Caviness, V. S., & Swartz, M. N. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301073280104 · Cited by 1,344 · cited 1×
“The mortality rate after meningitis is generally highest at the extremes of age, but overall is in the range of 5–10% for children 43 and has been reported to be as high as 25% for adults.(44) The case fatality rate for pneumococcal meningitis in particular, however, is the highest among the bacterial pathogens, appro…”
BackgroundIncreasing Prevalence of Multidrug-Resistant Streptococcus pneumoniae in the United States
Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Lexau, C., Reingold, A., Lefkowitz, L., Cieslak, P. R., Cetron, M., Zell, E. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432603 · Cited by 888
Effectiveness of Pneumococcal Polysaccharide Vaccine in Older Adults
Jackson, L. A., Neuzil, K. M., Yu, O., Benson, P., Barlow, W. E., Adams, A. L., Hanson, C. A., Mahoney, L. D., Shay, D. K., & Thompson, W. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022678 · Cited by 608
Cited by
Insights into the Interaction between Influenza Virus and Pneumococcus
McCullers, J. A. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-05 · Cited by 846
“The pneumococcus has historically been the most common etiologic agent of community-acquired pneumonia, as well as bacterial meningitis, otitis media, and sepsis (16, 44, 118, 168).”
BackgroundSecondary bacterial infections associated with influenza pandemics
Morris, D. E., Cleary, D. W., & Clarke, S. C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01041 · Cited by 576
Streptococcus pneumoniae’s Virulence and Host Immunity: Aging, Diagnostics, and Prevention
Brooks, L. R. K., & Mias, G. I. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01366 · Cited by 286
Daniels, C. C., Rogers, P. D., & Shelton, C. M. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.1.27 · Cited by 273
“J Pediatr Pharmacol Ther 2016;21(1):27–35”
McCullers, J. A., McAuley, J. L., Browall, S., Iverson, A. R., Boyd, K. L., & Henriques Normark, B. (2010) · The Journal of Infectious Diseases · doi:10.1086/656333 · Cited by 218
Metadata
- Authors
- Bridy‐Pappas, A. E., Margolis, M. B., Center, K. J., & Isaacman, D. J.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2005-09
- Volume
- 25
- Issue
- 9
- Pages
- 1193-1212
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2035510605
- Cited by
- 108
- References
- 4
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.